
CAS 1103500-20-4
:Formula:C28H27Cl2N3O4
InChI:InChI=1S/C28H27Cl2N3O4/c1-32-14-20(28(34)35)19-8-7-17(13-24(19)32)33-11-9-18(10-12-33)36-15-21-26(31-37-27(21)16-5-6-16)25-22(29)3-2-4-23(25)30/h2-4,7-8,13-14,16,18H,5-6,9-12,15H2,1H3,(H,34,35)
InChI key:RPVDFHPBGBMWID-UHFFFAOYSA-N
SMILES:CN1C=C(C2=C1C=C(C=C2)N3CCC(CC3)OCC4=C(ON=C4C5=C(C=CC=C5Cl)Cl)C6CC6)C(=O)O
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
LY2562175
CAS:LY2562175 is an effective and selective FXR agonist (EC50: 193 nM).Formula:C28H27Cl2N3O4Purity:99.16% - 99.63%Color and Shape:SolidMolecular weight:540.438LY2562175
CAS:6-(4-((5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acidFormula:C28H27Cl2N3O4Purity:99%Molecular weight:540.44LY2562175
CAS:Controlled ProductLY2562175 is a small molecule that inhibits diacylglycerol (DAG) production. It binds to the enzyme DAG kinase, which is responsible for catalyzing the phosphorylation of DAG to form phosphatidic acid. LY2562175 has been shown to reduce lipid levels in humans and improve dyslipidemia. LY2562175 also has inhibitory activity against primary sclerosing cholangitis, a chronic inflammatory condition of the bile ducts in the liver. The mechanism of action for this drug is not fully understood but it may be due to its ability to inhibit cell proliferation and the production of pro-inflammatory cytokines by immune cells. LY2562175 has undergone clinical trials as a diagnostic tool for primary sclerosing cholangitis and safety profiles have been evaluated in pharmacokinetic studies.Formula:C28H27Cl2N3O4Purity:Min. 95%Molecular weight:540.44 g/mol





